Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03524508 |
Recruitment Status :
Completed
First Posted : May 14, 2018
Last Update Posted : August 24, 2022
|
Sponsor:
Changhoon Yoo
Collaborators:
Ulsan University Hospital
Chungnam National University Hospital
Kyungpook National University Chilgok Hospital
Inje University
Information provided by (Responsible Party):
Changhoon Yoo, Asan Medical Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | September 30, 2020 |
Actual Study Completion Date : | December 31, 2021 |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):